March 25, 2026

Introducing PD-L1 22C3 FDA for Ovarian Carcinoma

As a reminder, PD-L1 22C3 FDA for Ovarian Carcinoma is now available to support precision oncology in ovarian cancer patients. This advanced immunohistochemistry (IHC) assay empowers clinicians to support patients with recurrent ovarian cancer who may benefit from a new targeted therapy. This advanced immunohistochemistry (IHC) assay detects PD-L1 protein expression in ovarian carcinoma and is performed in accordance with manufacturer specifications, utilizing the FDA-approved PD-L1 IHC 22C3 pharmDx. The assay utilizes the 22C3 clone with Combined Positive Score (CPS) assessment and integrates into established laboratory workflows. Testing is available: As a standalone PD-L1 companion diagnostic assay As part of the NeoTYPE Ovarian Tumor Profile, which consolidates HER2, FOLR1, and PD-L1 testing within a single ovarian biomarker framework. NeoTYPE Ovarian Tumor Profile previously included PD-L1 LDT, our new PD-L1 22C3 FDA for Ovarian Carcinoma replaces the LDT in this profile. For cases requiring broader molecular insights, PanTracer Pro may be utilized to complement IHC-based biomarker evaluation through comprehensive genomic profiling (CGP). Ordering information: Rapid Turnaround Time: Global: 2 days, Tech-Only: 1 day Level of Service: Global and Tech-Only CPT Code*: 88360x1 NYS Approved: Yes Updated test requisition forms are available. As a trusted leader in oncology diagnostics, NeoGenomics has delivered reliable PD-L1 testing for years, understanding its critical role in guiding treatment strategies. With this FDA-approved companion diagnostic, we’re reinforcing our commitment to delivering high-quality, actionable results that drive informed decision-making and improve patient outcomes. *The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

AML and Expanded MPN NGS Testing – Now Available in New York State

AML Express™ and myeloproliferative neoplasm (MPN) next-generation sequencing (NGS) testing are now available in New York State. The AML Express panel supports better outcomes for acute myeloid leukemia (AML) patients with rapid and detailed genetic insights to guide treatment decisions. Its comprehensive NGS-based assessment delivers rapid diagnostic, prognostic, and therapeutic information to make informed, personalized treatment decisions. Additionally, expanded MPN NGS testing delivers enhanced analytical sensitivity, broader exon coverage for the JAK2 gene, and a faster turnaround time of 7 days or less for all tests. The following assays are fully validated and available in New York State: AML Express MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12–15, CALR, and MPL JAK2 V617F Mutation Analysis by NGS JAK2 Extended (Exon 12–15 nonV617F) Mutation Analysis by NGS CALR Mutation Analysis by NGS MPL Mutation Analysis by NGS IMPORTANT: You can find these tests in the NeoTYPE/NextGen Sequencing section of NeoLINK when placing an online order. The MPN NGS assays will replace the current tests that are performed by PCR, bi-directional sequencing and/or fragment length analysis (FLA). Orders of the old tests will be automatically accessioned for the new tests. If you have any questions, please reach out to your Sales Representative or visit our website to learn about our testing services. You can reach our dedicated Client Services team at 866.776.5903, option 3, or Client.Services@NeoGenomics.com Interface Clients: This test update will involve changes to test names and codes. Please refer to the Interface Updates section for more info.   Every Patient Is Unique – Your Testing Should Be Too Due to the significant overlap in disease presentation, hematological disorders and malignancies can be initially misdiagnosed. With over 100 different subtypes of leukemias, lymphomas, and myelomas, reaching a definitive diagnosis requires expertise to manage ever-evolving clinical guidelines and testing criteria. The Compass® suite of services is focused on your patients’ individual characteristics and is guided by board-certified hematopathologists with expertise in the diagnosis and treatment of hematologic malignancies. This consultative service will result in a final report and definitive diagnosis for your patient. Compass: A sample-to-diagnosis service guided by board-certified hematopathologists to arrive at a definitive and actionable diagnosis for over 100 different types of hematologic malignancies. Only medically necessary tests are performed based on clinical history, laboratory information, and recommended guidelines. Compass Select: A diagnostic solution designed to support pathologists. With Compass Select, hematopathologists at NeoGenomics will integrate existing morphologic testing completed locally with our comprehensive testing menu to arrive at a definitive diagnosis. Chart: A personalized report uniquely for Compass patients for monitoring response to therapy, assessing residual disease, and determining disease progression. This is a solution for any patient with a hematologic malignancy requiring long-term disease assessment and evaluation of treatment efficacy. For a complete list of recent test updates, click here for a downloadable document to view the impacted interface test codes.